ClinicalTrials.gg
CompletedNCT06033742Updated Sep 13, 2023

A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10374 in Healthy Subjects

A Phase 1 interventional study of HS-10374 tablets and HS-10374-matched placebo tablets in Psoriasis, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-13.

Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 9 months after the study started (first participant enrolled Nov 2021, registered Aug 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Psoriasis by Hansoh Pharmaceutical Group Company Limited — 7 open to participants now, 7 under way, 2 of them phase 3. Psoriasis · Hansoh Pharmaceutical Group Company Limited.

Enrollment
8th of 10
84 · median 131
Started
2021
the only one that year
Phase 1
4 of 10
1 open now
Registered
1st of 10
by date

Among the 10 studies in Psoriasis by Hansoh Pharmaceutical Group Company Limited, this one is the 8th largest by enrollment, is the only one that started in 2021, is one of 4 in phase 1, and was the 1st registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

7 of the 10 studies in Psoriasis by Hansoh Pharmaceutical Group Company Limited are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Psoriasis by Hansoh Pharmaceutical Group Company Limited, or all of them as a file.
02

Study summary

The purpose of this first-in-human study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of HS-10374 in healthy subjects.

03

Conditions studied

  • Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male or female subjects between the ages of 18-45 years
  2. Have no ; or agree to use a highly effective method of , and refrain from donating sperm or eggs during the study period and for at least 6 months after last dosing
  3. Have signed the form approved by the IRB

Exclusion criteria

Exclusion Criteria:

  1. Have a infection currently or within past 30 days, or have a history of active tuberculosis; or have positive screening test for infectious disease, including tuberculosis, viral hepatitis, AIDS and syphilis
  2. Have a history of or current allergic disease
  3. Have a history of drug or alcohol abuse or currently positive test result(s) for alcohol or drugs of abuse
  4. Smokers smoked ≥5 cigarettes per day within past 3 months or have a positive test result for nicotine
  5. Clinically significant abnormal physical examination, vital signs, clinical laboratory values, ECGs or imaging tests
  6. Pregnant or breastfeeding female subjects
  7. Have received hormone-based , drugs that prolong the , drugs that may cause drug interactions with product, , vaccines or other drugs within a specific period
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    HS-10374

    Single and multiple ascending doses of HS-10374 orally

    Drug: HS-10374 tablets

  • Placebo comparator
    Placebo

    Single and multiple ascending doses of HS-10374-matched placebo orally

    Drug: HS-10374-matched placebo tablets

Interventions

  • Single or multiple dosing of HS-10374 orally in a fasting state

  • DrugHS-10374-matched placebo tablets

    Single or multiple dosing of HS-10374-matched placebo orally in a fasting state

06

What researchers measure

Primary outcomes

  1. Incidence, severity and association with the study drug of adverse events (AEs), serious AEs (SAEs), and AEs leading to discontinuation

    Time frame: Day 1 up to Day 12 (SAD), Day 1 up to Day 42 (MAD)

  2. Number of participants with clinical laboratory abnormalities

    Clinical laboratory tests include hematology, urinalysis, stool analysis, blood chemistry, coagulation testing, Cystatin C, urine β2-microglobulin, erythrocyte sedimentation rate, C-reactive protein, etc.

    Time frame: Day 1 up to Day 12 (SAD), Day 1 up to Day 42 (MAD)

  3. Number of participants with abnormalities of vital signs

    Vital sign measured include blood pressure, pulse rate, temperature, and respiration rate.

    Time frame: Day 1 up to Day 12 (SAD), Day 1 up to Day 42 (MAD)

  4. Number of participants with abnormalities of physical examination

    Physical examination includes assessments of general appearance, skin, lymph nodes, head, neck, lung, heart, abdomen, spine, extremities, nervous system, etc.

    Time frame: Day 1 up to Day 12 (SAD), Day 1 up to Day 42 (MAD)

  5. Number of participants with abnormalities of electrocardiogram (ECG) parameters

    ECG parameters include heart rate, PR interval, RR interval, QRS duration, QTcF interval.

    Time frame: Day 1 up to Day 12 (SAD), Day 1 up to Day 42 (MAD)

Secondary outcomes

  1. Cmax

    Maximum plasma concentration

    Time frame: Day 1 up to Day 6 (SAD), Day 1 up to Day 19 (MAD)

  2. Tmax

    Time to reach Cmax

    Time frame: Day 1 up to Day 6 (SAD), Day 1 up to Day 19 (MAD)

  3. AUC

    Area under the plasma concentration-time curve

    Time frame: Day 1 up to Day 6 (SAD), Day 1 up to Day 19 (MAD)

  4. t½

    Terminal half-life

    Time frame: Day 1 up to Day 6 (SAD), Day 1 up to Day 19 (MAD)

  5. CL/F

    Apparent clearance

    Time frame: Day 1 up to Day 6 (SAD), Day 1 up to Day 19 (MAD)

  6. Vz/F

    Apparent volume of distribution

    Time frame: Day 1 up to Day 6 (SAD), Day 1 up to Day 19 (MAD)

  7. Rac

    Accumulation ratio

    Time frame: Day 1 up to Day 6 (SAD), Day 1 up to Day 19 (MAD)

07

Study locations

1 site
  • Huashan Hospital Affiliated to Fudan University
    Shanghai, Shanghai 200040, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Mar 2023, 16 months.

Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 16 months is above that.

Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2023
First posted
Sep 13, 2023
StartActual
Nov 13, 2021
Primary completionActual
Mar 24, 2023
CompletionActual
Mar 24, 2023
Last update
Sep 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06033742
Responsible party
Sponsor
First posted
Sep 13, 2023
Start date
Nov 13, 2021
Primary completion
Mar 24, 2023
Completion
Mar 24, 2023
Last update
Sep 13, 2023

Study contacts

Jing Zhang, PhD
principal investigator · Huashan Hospital
Jinhua Xu, MD
principal investigator · Huashan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HS-10374

Start the discussion